Published: September 27, 2019

Introduction {#sec1}
============

γ-Aminobutyric acid (GABA) and glycine are the major inhibitory neurotransmitters in the brain ([@bib36]). Glycine receptor (GlyR) and GABA type A receptor (GABA~A~R) are members of a large Cys-loop superfamily and are structurally similar ligand-gated ion channels ([@bib25], [@bib21]). On activation, the GlyR and GABA~A~R selectively conduct Cl^−^ through central pores, leading to neuron hyperpolarization and inhibitory neurotransmission in the central nervous system ([@bib36]). These receptors are usually localized at the synapse postsynaptically ([@bib15], [@bib26]). Emerging evidence has suggested that certain isoforms of GABA~A~R, including α~5~ subunit-containing receptors, can be found pre-synaptically and extra-synaptically ([@bib8], [@bib9], [@bib12], [@bib22], [@bib18]). GlyR is widely distributed in the central nervous system, particularly in the brainstem and spinal cord ([@bib19], [@bib55]). To date, four α-subunits (α~1~-~4~) and one β-subunit of GlyR have been identified. All GlyR α subunits can form functional homomeric channels that are mainly located on the pre- and extra-synaptic membrane of a synapse ([@bib19], [@bib55], [@bib32], [@bib49]). However, after co-assembling with the α subunits, the β subunit can form functional postsynaptic heteromeric αβ channels ([@bib37], [@bib55]).

Hyperekplexia is a human genetic neurological disorder usually caused by point mutations in α~1~ GlyRs ([@bib42]). Although rare, this disease can be life-threatening in children and is characterized by exaggerated startle response and muscle stiffness following an unexpected stimulus. Numerous point mutations in the GlyR α~1~ subunit have been identified and characterized as hyperekplexic mutations disrupting GlyR function ([@bib5]). Among them, the R271Q was the most common dominant GlyRα~1~ mutation identified in patients with hyperekplexia ([@bib47]). Despite strong evidence suggesting that the point mutations in the α~1~ GlyR are strongly associated with hyperekplexia, the primary therapeutic agent effectively used to treat hyperekplexia in humans is benzodiazepines ([@bib13], [@bib17], [@bib48]), which selectively enhances GABA~A~R functioning ([@bib14], [@bib30]). Thus, GABA~A~Rs seems to be the primary therapeutic target in hyperekplexia. Consistently, a previous investigation revealed a deficiency in both glycinergic and GABAergic transmission in the spinal cord of R271Q mutant mice ([@bib2], [@bib50]). Unfortunately, the cellular and molecular mechanisms underlying the GABA~A~R deficiency in hyperekplexia remains unclear. Such deficiency is not caused by the posttranslational modification of either GlyR or GABA~A~R protein since radioligand binding to these receptors was unaffected ([@bib2]). The speculation that GlyR can cross-talk or interact with GABA~A~R has been long-standing ([@bib52]). These receptors are abundant in the spinal cord and brainstem where the neurotransmitters GABA and glycine are colocalized and co-released from the same vesicles at many motoneuron synapses ([@bib23]). Strong evidence suggests that a substantial proportion of spinal cord inhibitory synapses host both GlyRs and GABA~A~Rs. Nevertheless, direct evidence and the *in vivo* consequence of the potential GlyR-GABA~A~R interaction have not been reported. Considering these questions, we conducted experiments using various approaches to explore the nature of the interaction through which hyperekplexic mutations in the GlyR α~1~ subunits disrupt GABA~A~R functioning at synapses.

Results {#sec2}
=======

GABA~A~Rs Deficiency in the Brainstem of Hyperekplexic Mutant Mice {#sec2.1}
------------------------------------------------------------------

To determine whether the hyperekplexic point mutations in the α~1~ GlyR could affect GABAergic transmission, we measured GABA release and GABA~A~R functioning using patch clamp recording in the hypoglossal nucleus slices from two transgenic mouse lines carrying GlyRα~1~ R271Q and S267Q hyperekplexic point mutations. Another mouse line carrying GlyRα~1~ M287L point mutation was set as a negative control since this mutation was not found in patients with hyperekplexia and has been previously shown to scarcely change the function of GlyR in mice ([@bib5], [@bib55]). Both the frequency and amplitude of GABAergic spontaneous inhibitory postsynaptic currents (sIPSCs) were remarkably attenuated in the hypoglossal nucleus of GlyRα~1~^R271Q^ and GlyRα~1~^S267Q^ but not in GlyRα~1~^M287L^ mutant mice ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}). Consistently, the electrical stimulation-evoked GABAergic IPSCs (eIPSCs) and the puffing GABA-induced currents were both significantly reduced in the GlyRα~1~^R271Q^ and GlyRα~1~^S267Q^ mutant mice ([Figures 1](#fig1){ref-type="fig"}B and 1C).Figure 1Dysfunction of GABA~A~Rs in the Hyperekplexic Mutant Mice(A) Trace records, average frequency, and amplitude of GABAergic sIPSCs in brainstem hypoglossal nucleus slices from WT, GlyRα~1~^R271Q^, and GlyRα~1~^S267Q^ mutant mice.(B) Trace records and average amplitude of GABAergic eIPSCs in brainstem hypoglossal nucleus slices from WT and GlyRα~1~^R271Q^ mutant mice.(C) Trace records and average values of GABA maximal current induced by puffing 1 mM GABA in brainstem hypoglossal nucleus slices from WT and GlyRα~1~^S267Q^ mutant mice.(D) Trace records, average frequency, and amplitude of GABAergic mIPSCs in brainstem hypoglossal nucleus slices from WT and GlyR α~1~^S267Q^ mutant mice.(E) Trace records and average values of BSTC in brainstem hypoglossal nucleus slices from WT and GlyRα~1~^S267Q^ mutant mice.All digits within the columns represent numbers of cells measured from at least three mice. Data are represented as mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 based on unpaired t tests; ns, not significant (p \> 0.05).

Next, we separately examined the function of GABA~A~Rs at various synaptic locations including the pre-, post-, and extra-synapses. Here the GlyRα~1~^S267Q^ mice were used as a representative. The frequency but not the amplitude of the GABAergic mIPSCs was significantly decreased in the brainstem hypoglossal nucleus of the GlyRα~1~^S267Q^ mice compared with that in the wild-type (WT) littermates ([Figure 1](#fig1){ref-type="fig"}D). This suggests that a pre- but not post-synaptic impairment exists in GABAergic transmission. Then, we tested the bicuculline-sensitive tonic current (BSTC), which represents extra-synaptic GABA~A~R activity. The amplitude of the BSTC was also significantly reduced in the GlyRα~1~^S267Q^ mice compared with that in the WT littermates ([Figure 1](#fig1){ref-type="fig"}E).

Hyperekplexic GlyRα~1~ Mutations Cause GABA~A~R Deficiency when Co-expressed in HEK-293 Cells {#sec2.2}
---------------------------------------------------------------------------------------------

Mutant GlyRs may disrupt the function of GABA~A~Rs in the same neuron since the preponderance of evidence has indicated a wide colocalization of GlyRs and GABA~A~Rs in brainstem neurons ([@bib34], [@bib35], [@bib28], [@bib29], [@bib51]). Next, we investigated whether the GlyRα~1~ mutations could induce GABA~A~R deficiency if these receptors were co-expressed in HEK-293 cells. The GlyRα~1~^R271Q^ and GlyRα~1~^S267Q^ hyperekplexic point mutations significantly reduced the maximal amplitudes of the current (*I*~*max*~) activated by puffing glycine ([Figures 2](#fig2){ref-type="fig"}A and 2B) and GABA ([Figures 2](#fig2){ref-type="fig"}A and 2C). GlyRα~1~^R271Q^ and GlyRα~1~^S267Q^, but not GlyRα~1~^M287L^, mutations shifted the dose-response curve of the GABA current to the right ([Figures 2](#fig2){ref-type="fig"}D and 2E) and increased the half-maximal effective concentration (EC~50~) values of the GABA~A~Rs ([Figure 2](#fig2){ref-type="fig"}E). Interestingly, the other two GlyR α subunits, including α~2~ and α~3~, exhibited the same characteristics as α~1~ subunit in impairing GABA~A~R functions. For instance, the point mutations in the GlyRα~2~ (R305Q) and GlyRα~3~ (R320Q) subunits corresponding to R271Q of GlyRα~1~ not only reduced the glycine *I*~*max*~ ([Figure 2](#fig2){ref-type="fig"}F) when expressed alone but also inhibited GABA *I*~*max*~ when co-expressed with GABA~A~Rs ([Figure 2](#fig2){ref-type="fig"}G).Figure 2Impairment in GABA~A~Rs by Hyperekplexic GlyR α~1~ Mutations in HEK-293 Cells(A) Representative trace records of glycine *I*~*max*~ (up) and GABA *I*~*max*~ (down) separately induced by 1 mM glycine and GABA in HEK-293 cells co-expressing GABA~A~Rs (α~1~β~2~γ~2~) and various hyperekplexic mutant α~1~ GlyRs.(B) The average values of glycine *I*~*max*~ induced by 1 mM glycine in HEK-293 cells co-expressing GABA~A~Rs (α~1~β~2~γ~2~) and various hyperekplexic mutant α~1~ GlyRs. The data were normalized to the *I*~*max*~ of the GlyRα~1~^WT^ group.(C) Average values of GABA *I*~*max*~ induced by 1 mM GABA in HEK-293 cells co-expressing GABA~A~Rs and various hyperekplexic mutant α~1~ GlyRs. The data were normalized to their respective controls (GlyRα~1~^WT^ group).(D and E) Dose-response curves of *I*~*GABA*~ in HEK-293 cells co-expressing GABA~A~Rs (α~1~β~2~γ~2~) and either WT, α~1~^R271Q^, α~1~^S267Q^, or α~1~^M287L^ GlyRs. The data were normalized to *I*~*max*~ of the GlyRα~1~^WT^ group (D) or its own group (E).(F) The average values of glycine *I*~*max*~ in HEK-293 cells expressing WT or α~2~^R305Q^ or α~3~^R320Q^ GlyRs.(G) The average values of GABA *I*~*max*~ in HEK-293 cells co-expressing GABA~A~Rs (α~1~β~2~γ~2~) and WT or α~2~^R305Q^ or α~3~^R320Q^ GlyRs.All digits within the columns represent numbers of cells measured. Data are represented as mean ± SEM. \*\*p \< 0.01, \*\*\*p \< 0.001 based on unpaired t tests; ns, not significant (p \> 0.05).

At high concentrations, GABA can also activate GlyRs ([Figure S2](#mmc1){ref-type="supplementary-material"}) ([@bib44]). Thus, we examined the efficacy of muscimol, which is a full agonist specific for GABA~A~R but not GlyR ([@bib46]) ([Figure S3](#mmc1){ref-type="supplementary-material"}A), in activating GABA~A~R-GlyR complexes. Consistent with our observation in the above-mentioned experiments using GABA, the amplitude of muscimol (100 μM)-induced maximal current (*I*~*max*~) was also significantly decreased in HEK-293 cells co-expressing GABA~A~Rs with GlyRα~1~^R271Q^ or GlyRα~1~^S267Q^ ([Figure S3](#mmc1){ref-type="supplementary-material"}B).

The Protein-Protein Interactions between GABA~A~R and Hyperekplexic Mutant GlyR {#sec2.3}
-------------------------------------------------------------------------------

First, we investigated whether the hyperekplexic mutations will affect the membrane trafficking of GlyR and GABA~A~R. The western-blotting results showed that both the S267Q and R271Q point mutations in the GlyRα~1~ subunit did not affect the protein expression level of GlyR or GABA~A~R in plasma membranes extracted from HEK-293 cells co-transfected with the cDNA of GlyRα~1~^WT^, GlyRα~1~^R271Q^, and GlyRα~1~^S267Q^ with or without GABA~A~Rs ([Figure S4](#mmc1){ref-type="supplementary-material"}).

A possible mechanism of the GABA~A~R deficiency in the presence of mutant GlyRs is that there may exist an interaction between GlyR and GABA~A~R proteins. To test this hypothesis, we conducted a co-immunoprecipitation (Co-IP) assay of mutant or WT GlyRα~1~ subunits and GABA~A~Rs (α~1~β~2~γ~2~) co-expressed in HEK-293 cells. The point mutations R271Q and S267Q, but not M287L, significantly increased the amount of GlyR protein co-immunoprecipitated with GABA~A~R proteins from whole cell lysates ([Figures 3](#fig3){ref-type="fig"}A, [S5](#mmc1){ref-type="supplementary-material"}, and [S6](#mmc1){ref-type="supplementary-material"}) and plasma membrane preparations ([Figure S7](#mmc1){ref-type="supplementary-material"}). Similar results were observed *in vivo* in transgenic mice carrying GlyRα~1~ mutations. The association between the GlyRs and GABA~A~Rs was remarkably enhanced in the brainstem of the GlyRα~1~^R271Q^ ([Figures 3](#fig3){ref-type="fig"}B and [S8](#mmc1){ref-type="supplementary-material"}A--S8C) and GlyRα~1~^S267Q^ ([Figures 3](#fig3){ref-type="fig"}C and [S8](#mmc1){ref-type="supplementary-material"}D--S8F), but not GlyRα~1~^M287L^, mutant mice ([Figures 3](#fig3){ref-type="fig"}D and [S8](#mmc1){ref-type="supplementary-material"}G--S8I).Figure 3Identification of Interaction between GABA~A~R and Hyperekplexic Mutant GlyRs(A) GlyRα~1~ was purified using GABA~A~R α~1~ antibodies in HEK-293 cells co-expressing GABA~A~Rs (α~1~β~2~γ~2~) and WT/mutant α~1~ GlyRs, and the co-precipitating proteins were detected by immunoblotting. Inputs are immunoblots of the same protein in cell lysates before Co-IP. Quantification of WT and mutant GlyR α~1~ binding to GABA~A~R α~1~ subunits (n = 3). The data were normalized to the WT group.(B and C) Endogenous brainstem GlyRα~1~ of WT and GlyRα~1~ R271Q (B) or S267Q (C) KI mice was purified using GABA~A~R α~1~ antibodies, and the co-precipitating proteins were detected by immunoblotting. Inputs are immunoblots of the same protein in tissue lysates before Co-IP. Quantification of WT and R271Q (B) or S267Q (C) mutant GlyRα~1~ binding to GABA~A~Rα~1~ (n = 3 mice).(D) Endogenous brainstem GlyRα~1~ of WT and GlyRα~1~ M287L KI mice was purified using GABA~A~R α~1~ antibodies, and the co-precipitating proteins were detected by immunoblotting. Inputs are immunoblots of the same protein in tissue lysates before Co-IP. Quantification of WT and M287L mutant GlyRα~1~ binding to GABA~A~Rα~1~ (n = 3 mice). The data were normalized to the WT group.Data are represented as mean ± SEM. \*p \< 0.05, \*\*\*p \< 0.001 based on unpaired t tests; ns, not significant (p \> 0.05).

The Site R271 Is Critical for the Interaction between GABA~A~R and Hyperekplexic Mutant GlyR {#sec2.4}
--------------------------------------------------------------------------------------------

Subsequently, we conducted a molecular dynamic simulation to evaluate the interaction between the subunits of GABA~A~Rs ([@bib33]) and hyperekplexic mutant GlyR subunits ([@bib20]) in different combinations of dimers. First, all simulations were reliable since no unexpected collapse of protein structures were observed ([Figure S9](#mmc1){ref-type="supplementary-material"}). Then, the binding affinities between the subunits in the dimers, including GABA~A~R homer-dimers (GB/GB) and GABA~A~R bound with GlyR (GB/GR) or GlyR mutant (GB/GRM), were analyzed and compared. Among the WT receptor combinations, two subunits in the GB/GB complex showed the strongest binding affinity with a binding free energy (BFE) of −121.9 ± 4.3 kcal/mol. However, the binding affinities in the GB/GR complex were much weaker (−89.2 ± 8.9 kcal/mol). A significant decrease in BFE was observed between the subunits in GB/GRM ([Figure 4](#fig4){ref-type="fig"}B). Notably, the BFE value in GB/GRM was as low as −123.4 ± 14.3 kcal/mol, which is highly similar to the value observed in GB/GB. Further analysis indicates that the mutation of R271Q may lead to hydrogen bonding with TYR227 instead of GLN231 on GABA~A~R ([Figure 4](#fig4){ref-type="fig"}A). The R271Q mutation promotes a conformational change in the GB and GR subunits, leading to more intensive H-bond formation and a larger contact surface area between the subunits ([Figures 4](#fig4){ref-type="fig"}C and 4D).Figure 4Molecular Dynamic Simulation, Mutagenesis, and Correlation Analysis(A) Overview of residues forming H-bond between GB chain and GR chain in the GB/GR and GB/GRM complexes at the end of the simulation. GB chain and residue labels are colored in cyan. GR chain and residue labels are colored in pink. H-bonds are shown by the red dashed line.(B) Binding energy (kcal/mol) between subunits in various composing form of dimers.(C) Number of H-bonds formed between GB chain and GR chain in the GB/GR and GB/GRM complexes. The data are shown as averages of each 200 ps. Data are represented as mean ± SD.(D) VDW contact surface between GB chain and GR chain in the GB/GR and GB/GRM complexes. Proteins are displayed in lines. Contact surfaces were mapped and colored according to the distances between two chains.(E) Average values of GABA *I*~*max*~ induced by 1 mM GABA in HEK-293 cells co-expressing GABA~A~Rs and various R271 site mutant GlyR α~1~ subunits. All data were normalized to their respective controls (WT group).(F) Correlation analysis of CoMSIA values of various amino acids at 271 and the percentage inhibition of GABA *I*~*max*~.(G) GlyRα~1~ was purified using GABA~A~R α~1~ antibodies in HEK-293 cells co-expressing GABA~A~Rs (α~1~β~2~γ~2~) and GlyRα~1~ carrying various R271 mutations, and the co-precipitating proteins were detected by immunoblotting. Inputs are immunoblots of the same protein in cell lysates before Co-IP. Quantification of WT and R271 mutant GlyRα~1~ binding to GABA~A~R α~1~ (n = 3). Data were normalized to the WT group.(H) Correlation analysis of the percentage decrease in GABA *I*~*max*~ and amount of R271 mutant α~1~ GlyRs co-immunoprecipitated with GABA~A~Rs.All digits within the columns represent numbers of cells measured. Data are represented as mean ± SEM. \*\*p \< 0.01, \*\*\*p \< 0.001 based on unpaired t tests; ns, not significant (p \> 0.05).

To obtain further molecular insight into the role of site R271 in the association between GABA~A~Rs and GlyRs, we used mutagenesis to analyze the interrelationship between the function of GABA~A~Rs and the biophysical properties of the amino acid residue at 271 of the GlyRα~1~. The mutation-induced decrease in glycine *I*~*max*~ ([Figure S10](#mmc1){ref-type="supplementary-material"}A) and GABA *I*~*max*~ ([Figure 4](#fig4){ref-type="fig"}E) varied substantially. No correlation was observed between the percentage inhibition of glycine *I*~*max*~ and that of GABA *I*~*max*~ ([Figure S10](#mmc1){ref-type="supplementary-material"}B), suggesting that the dysfunction in GABA~A~R does not depend on the efficacious levels of GlyRs. Then, to examine the biophysical properties of the amino acid residue at 271 of the GlyRα~1~, we performed a comparative molecular similarity index analysis (CoMSIA), which is a comprehensive method evaluating polarity, electrostatic potential, and steric property. A strong correlation was observed between the CoMSIA values of various amino acids at 271 and the function of GlyRs ([Figure S10](#mmc1){ref-type="supplementary-material"}C) or GABA~A~Rs ([Figure 4](#fig4){ref-type="fig"}F). Combined with the results of the molecular dynamics simulation, the R271Q point mutation likely suppresses the function of GlyR by altering the protein conformational change required for channel gating. This point mutation also disrupted GABA~A~R functioning by enhancing the interaction between GlyR and GABA~A~R. To further test this hypothesis, we performed a Co-IP assay to examine the interaction between the mutant R271E/L/K/G α~1~ GlyRs and GABA~A~Rs co-expressed in HEK-293 cells. Both the GlyRα~1~ subunits and GABA~A~Rα~1~ subunits were identified in the co-immunoprecipitants pulled down by the GABA~A~Rα~1~ antibodies ([Figures 4](#fig4){ref-type="fig"}G and [S11](#mmc1){ref-type="supplementary-material"}A--S11C). Among the four GlyRα~1~ R271 mutations, the R271L and R271E mutations appeared to enhance the binding of GlyR to GABA~A~R. The protein levels of GlyRα~1~^R271X^ bound to GABA~A~Rα~1~ were significantly and positively correlated with the extent of the GABA~A~R deficiency, although their levels substantially varied ([Figure 4](#fig4){ref-type="fig"}H).

GlyR β Subunits Restore Dysfunction of GABA~A~Rs Caused by GlyR α~1~ Mutations {#sec2.5}
------------------------------------------------------------------------------

The above-mentioned results have suggested that the pre- and extra- but not post-synaptic GABA~A~Rs were impaired in hyperekplexia disease. It is worth mentioning that GlyR homomers (α/α) have been found to primarily reside at pre/extra-synaptic sites, whereas GlyR heteromers (α/β) are mostly post-synaptic ([@bib3], [@bib19], [@bib55], [@bib32], [@bib49]). Thus, a possible scenario is that different combinations of GlyR subunits may have distinct abilities to interact with GABA~A~Rs. To test this hypothesis, we performed the electrophysiological experiments and Co-IP assay. Addition of the GlyR β subunit indeed prevents the hyperekplexic point mutations in the α~1~ subunit from hijacking the GABA~A~Rs because no functional disruption in the GABA~A~R was observed after co-expressing the GlyR β subunits with the GlyRα~1~^R271Q^/GABA~A~R complexes in HEK-293 cells ([Figures 5](#fig5){ref-type="fig"}A and 5B). Furthermore, the GlyR β subunits also significantly interrupted the association between the mutant α~1~ GlyRs and GABA~A~Rs in HEK-293 cells ([Figures 5](#fig5){ref-type="fig"}C and [S12](#mmc1){ref-type="supplementary-material"}). These observations may hint at why only pre- and extra-synaptic GABA~A~Rs have been impaired in hyperekplexia.Figure 5GlyR β Subunits Restore GABA~A~Rs Functioning by Interrupting the Interaction between GABA~A~Rα~1~ and GlyRα~1~ Subunits(A) Average glycine *I*~*max*~ values in HEK-293 cells co-expressing GABA~A~Rs (α~1~β~2~γ~2~) and either homomeric or heteromeric hyperekplexic mutant α~1~/β GlyRs.(B) Average GABA *I*~*max*~ values in HEK-293 cells co-expressing GABA~A~Rs (α~1~β~2~γ~2~) and either homomeric or heteromeric hyperekplexic mutant α~1~/β GlyRs.(C) GlyRα~1~ was purified using GABA~A~R α~1~ antibodies in HEK-293 cells co-expressing GABA~A~Rs (α~1~β~2~γ~2~) and homomeric or heteromeric hyperekplexic mutant α~1~/β GlyRs, and the co-precipitating proteins were detected by immunoblotting. Inputs are immunoblots of the same protein in cell lysates before Co-IP. Quantification of WT and mutant GlyRα~1~ binding to GABA~A~R α~1~ (n = 3). Data were normalized to the WT group.All digits within the columns represent numbers of cells measured. Data are represented as mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 based on unpaired t tests; ns, not significant (p \> 0.05).

Colocalization and Interaction of α~5~-Containing GABA~A~Rs and Hyperekplexic Mutant GlyRs {#sec2.6}
------------------------------------------------------------------------------------------

Emerging evidence suggests that α~5~ subunits-containing GABA~A~R (α~5~β~x~γ~x~) is the primary form of pre- and extra-synaptic GABA~A~Rs in several brain regions, including the hippocampus, spinal cord, and brainstem ([@bib8], [@bib9], [@bib12], [@bib22]). Genetic deletion of α~5~-containing GABA~A~ receptor could also cause severe convulsive seizure ([@bib16]). Here, using RNAscope techniques, we conducted *in situ* hybridization and observed a high degree of colocalization of GlyRα~1~ and GABA~A~Rα~5~ subunit mRNAs in neurons in the hypoglossal nucleus of the brainstem in both the GlyRα~1~^S267Q^ and WT mice ([Figures 6](#fig6){ref-type="fig"}A, 6B, and [S13](#mmc1){ref-type="supplementary-material"}). Therefore, we next examined whether the hyperekplexic mutant GlyRs could also affect the α~5~-containing GABA~A~Rs. The GABA *I*~*max*~ was significantly decreased when the α~1~^S267Q^ mutant GlyRs were co-expressed with α~5~β~2~γ~2~ GABA~A~Rs in HEK-293 cells ([Figure 6](#fig6){ref-type="fig"}C). Compared with the WT, the S267Q point mutation significantly increased the amount of GlyRs co-immunoprecipitated with α~5~β~2~γ~2~ GABA~A~Rs in both the HEK-293 cells ([Figures 6](#fig6){ref-type="fig"}D and [S14](#mmc1){ref-type="supplementary-material"}A--S14C) and the brainstem of GlyRα~1~^S267Q^ mutant mice ([Figures 6](#fig6){ref-type="fig"}E and [S14](#mmc1){ref-type="supplementary-material"}D--S14F).Figure 6Interaction between α~5~-Containing GABA~A~R and Hyperekplexic Mutant GlyR(A) Representative confocal imaging showing the colocalization of GABA~A~Rα~5~ and GlyRα~1~ subunit mRNAs in the GlyRα~1~^S267Q^ mouse brainstem using RNAscope technology (scale bar, 25 μm).(B) Left, percentage of GlyRα~1~ mRNA--positive neurons that co-express GABA~A~Rα~5~ mRNA. Right, percentage of GABA~A~Rα~5~ mRNA--positive neurons that co-express GlyRα~1~ mRNA (n = 3 mice).(C) Trace records and average values of GABA *I*~*max*~ activated by 1 mM GABA in HEK-293 cells co-expressing GABA~A~Rs (α~5~β~2~γ~2~) and WT or α~1~^S267Q^ mutant GlyRs. The digits within the columns represent numbers of cells measured.(D) GABA~A~Rα~5~ was purified using GlyRα~1~ antibodies in HEK-293 cells co-expressing GABA~A~Rs (α~5~β~2~γ~2~) and WT/S267Q mutant GlyRα~1~, and the co-precipitating proteins were detected by immunoblotting. Inputs are immunoblots of the same protein in cell lysates before Co-IP. Quantification of GABA~A~R α~5~ binding to WT and S267Q mutant GlyR α~1~ (n = 3 mice).(E) Endogenous brainstem GABA~A~R α~5~ in WT and GlyRα~1~ S267Q KI mice were purified using GlyRα~1~ antibodies, and the co-precipitating proteins were detected by immunoblotting. Inputs are immunoblots of the same protein in tissue lysates before Co-IP. Quantification of mouse brainstem GABA~A~R α~5~ binding to WT and S267Q mutant GlyR α~1~ (n = 3 mice).Data are represented as mean ± SEM. \*\*p \< 0.01, \*\*\*p \< 0.001 based on unpaired t tests; ns, not significant (p \> 0.05).

Pre- and Extra-synaptic α~5~-Containing GABA~A~R Is a Therapeutic Target of Diazepam for Hyperekplexia Disease {#sec2.7}
--------------------------------------------------------------------------------------------------------------

Benzodiazepines (BZDs) have always been used as the first-line medication to treat patients with hyperekplexia in the clinic ([@bib13], [@bib17], [@bib48]). Therefore, we next assessed whether diazepam (DIA), the most common BZD, could rescue the pre- and extra-synaptic GABA~A~R deficiency in the brainstem hypoglossal nucleus of GlyRα~1~^S267Q^ KI mice. We conducted the following electrophysiological recordings, Co-IP experiments, and behavioral tests using homozygous and heterozygous GlyRα~1~^S267Q^ KI mice because most GlyRα~1~^R271Q^ KI mice died within 2--3 weeks ([Figure S15](#mmc1){ref-type="supplementary-material"}). DIA significantly rescued the reduced frequency of GABA mIPSCs ([Figure 7](#fig7){ref-type="fig"}A) and the attenuated amplitude of the BSTC ([Figure 7](#fig7){ref-type="fig"}B) in the brainstem hypoglossal nucleus of the GlyRα~1~^S267Q^ mutant mice. Consistently, DIA also significantly restored the attenuated GABA *I*~*max*~ in HEK-293 cells co-expressing α~5~-containing GABA~A~Rs and α~1~^S267Q^ GlyRs ([Figure S17](#mmc1){ref-type="supplementary-material"}A). These effects of DIA were remarkably diminished by Xli-093 ([Figures 7](#fig7){ref-type="fig"}A and 7B), which could specifically block DIA-induced potentiation on α~5~- ([Figure S16](#mmc1){ref-type="supplementary-material"}) but not α~1~/α~2~-containing GABA~A~Rs ([@bib10]) ([Figures S17](#mmc1){ref-type="supplementary-material"}B and S17C).Figure 7DIA Rescues Dysfunction of Pre- and Extra-synaptic α~5~-Containing GABA~A~Rs and Exaggerated Startle Responses in Hyperekplexic Mutant Mice(A) Trace records, average frequency, and amplitude of GABAergic mIPSCs in brainstem hypoglossal nucleus slices from WT and GlyR α~1~ S267Q mutant mice with or without diazepam (10 μM) and/or Xli-093 (1 μM) pre-incubation.(B) Trace records and average values of bicuculline-sensitive tonic currents (BSTC) in brainstem hypoglossal nucleus slices from WT and GlyR α~1~ S267Q mutant mice with or without diazepam (10 μM) and/or Xli-093 (1 μM) pre-incubation.(C) Hind feet clenching behavior in GlyRα~1~^S267Q^ mutant mice and effect of DIA (i.p. 10 mg/kg) and Xli-093 (intra-brainstem hypoglossal nucleus injection, 5 μg) on this behavior.(D) Average values of startle responses induced by white noise at 85, 90, and 95 dB in WT (n = 8) and GlyRα~1~^S267Q^ (n = 8) mice.(E) Average values of startle response activated by white noise at 85 dB in WT and GlyRα~1~^S267Q^ mutant mice with or without diazepam (i.p. 10 mg/kg) and/or Xli-093 (intra-brainstem hypoglossal nucleus injection, 5 μg) treatments.(F) Correlation analysis of fold increases in startle response, percentage decreases in mIPSC frequency, and amount of mutant α~1~ GlyRs co-immunoprecipitated with GABA~A~Rs in hyperekplexic mutant mice.All digits within the columns represent numbers of cells or mice measured. Data are represented as mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 based on unpaired t tests; ns, not significant (p \> 0.05).

Next, we investigated whether the restoration of pre- and extra-synaptic GABA~A~R functioning by DIA in the brainstem hypoglossal nucleus was sufficient to treat hyperekplexia. An intraperitoneal (i.p.) injection of DIA markedly alleviated hind feet clenching behaviors and exaggerated tremors in the GlyRα~1~^S267Q^ KI mice when the animals were picked up by their tails ([Figure 7](#fig7){ref-type="fig"}C). The therapeutic effect of DIA was completely abolished by an intra-brainstem hypoglossal nucleus microinjection of Xli-093 ([Figure 7](#fig7){ref-type="fig"}C). The GlyRα~1~^S267Q^ mutant mice displayed exaggerated startle reflexes in response to various acoustic stimuli ([Figure 7](#fig7){ref-type="fig"}D). The systemic administration of DIA significantly inhibited the exaggerated startle responses of the GlyRα~1~^S267Q^ KI mice. This DIA therapeutic effect was remarkably suppressed by an intra-brainstem hypoglossal nucleus injection of Xli-093 ([Figure 7](#fig7){ref-type="fig"}E). The startle reactions of the WT and various hyperekplexic mutant mice were significantly correlated with their brainstem hypoglossal nucleus presynaptic GABA~A~Rs deficiency (expressed as percentage decreases in mIPSC frequency) and the bonding strength between the GlyR and GABA~A~R (expressed as normalized GlyR-GABA~A~R CO-IP) ([Figure 7](#fig7){ref-type="fig"}F). Altogether, our results reveal that the pre- and extra-synaptic α~5~-containing GABA~A~R may be the major acting target of BDZ to treat hyperekplexia disease.

Discussion {#sec3}
==========

Both GABA~A~R and GlyR mediate rapid synaptic transmissions in the central nervous system ([@bib21], [@bib25]). Despite the widespread speculation that cross talk exists between these two types of receptors ([@bib41], [@bib43], [@bib31]), knowledge regarding the nature of such an interaction is limited. The data presented in this study provided several lines of evidence that primary hyperekplexic point mutations in the GlyR α~1~ subunit can suppress GABA~A~R functioning by hijacking GABA~A~Rs via protein interaction both *in vitro* and *in vivo*. This interaction underlies the pathological mechanism of hyperekplexia ([Figure 8](#fig8){ref-type="fig"}). First, hyperekplexic mutations in GlyR α~1~ subunits impair the functioning of both GlyRs and GABA~A~Rs in HEK293 cells and the mouse brainstem hypoglossal nucleus. Second, the mutant GlyRs are highly capable of forming hetero-oligomers with certain types of GABA~A~Rs. The R271Q point mutation increased the binding free energy, contact surface area, and number of hydrogen bonds between GABA~A~Rα~1~ and GlyRα~1~ protein. Third, the signal intensity of such GlyR-GABA~A~R complexes is highly correlated with the severity of the GABA~A~R deficiency and exaggerated startle responses in hyperekplexic mice.Figure 8Schematic of Mechanisms in which Hyperekplexic Mutant GlyRs Disrupt Inhibitory Neurotransmission by Interacting with Pre- and Extra-synaptic GABA~A~Rs(A) Under normal conditions, presynaptic GABA~A~Rs facilitate GABA release from GABAergic neuron terminals, activating postsynaptic GABA~A~Rs to inhibit neurons in the brainstem hypoglossal nucleus. The extra-synaptic GABA~A~Rs mediate the chronic inhibition of postsynaptic neurons in the brainstem hypoglossal nucleus.(B) In hyperekplexia disease, the mutant GlyRα~1~ binds to pre- and extra-synaptic GABA~A~Rs and, therefore, reduce GABA release and the chronic inhibition. The postsynaptic GlyRβ subunits prevent the mutant GlyRα~1~ from binding to the GABA~A~Rs.(C) DIA exerts its therapeutic effect by allosterically potentiating pre- and extra-synaptic α~5~-containing GABA~A~Rs in the brainstem hypoglossal nucleus.

In this study, weak binding between the WT GlyRs and GABA~A~Rs was observed in both the HEK-293 cells and brainstem tissues. This weak bonding is unlikely to affect the functioning of both ion channels because the glycine and GABA-activated currents did not show differences when the WT GlyRs and GABA~A~Rs were either separately expressed or co-expressed in the HEK-293 cells. In contrast, this weak binding may provide a possible explanation for the synergistic effects of glycine and GABA that have been observed in several previous reports ([@bib27], [@bib39]). For instance, a strong synergistic interaction has been observed between GABA and glycine in acutely isolated crucian carp retina neurons. The co-application of both agonists resulted in much larger responses (current \>400 pA) than either GABA or glycine alone (current \<20 pA) ([@bib27]). Another report also demonstrated that GABA and glycine can act synergistically at the spinal cord to generate a tonic inhibition of the micturition reflex pathway ([@bib39]). However, such bonding between GlyR and GABA~A~R does not appear to always be a good thing. In fact, the hyperekplexic mutations in GlyR caused stronger binding with GABA~A~R but remarkably impaired the functioning of both channels.

Site mutations generally attenuate the interaction between two associated proteins ([@bib40], [@bib45], [@bib4]). However, our findings reveal an entirely opposite pattern in the modulation of protein-protein interactions, particularly under pathological conditions. For instance, several hyperekplexic site mutations in GlyR α~1~, such as R271Q and S267Q, enhance its bonding interaction with GABA~A~R and therefore induce dysfunction in GABA~A~R. This mechanism may be universal since a similar pattern has been observed in several previous studies investigating the molecular and cellular mechanisms of various diseases. For instance, the R882H mutation in DNA (cytosine-5-)-methyltransferase 3α (DNMT3A) enhances its binding to polycomb repressive complex 1 (PRC1) protein and causes transcriptional silencing, suggesting that PRC1 favors R882 mutants over WT as binding partners in DNMT3A-mutated leukemia disease ([@bib24]). Furthermore, the H443P mutant NOD-like receptor (NLR) protein NLRC4 more strongly interacts with 19S proteasome ATPase Sug1 and ubiquitinated proteins in auto-inflammatory syndrome. This enhanced interaction triggers the constitutive caspase-8-mediated cell death ([@bib38]).

The hijacking of GABA~A~Rs by mutant GlyRs also results in a deficiency in major inhibitory neurotransmission. This finding is consistent with a previous study showing that the R271Q point mutation causes the hyperekplexia phenotype and impairs glycine and GABA transmission in mice ([@bib2], [@bib50]). The GlyR β subunit greatly reduces the formation of the GlyR-GABA~A~R complex, suggesting that the hijacking of the GABA~A~R by the mutant GlyRα~1~ subunits likely occurs in pre- or extra-synaptic sites where the GlyR β subunit is absent. Consistently, the low levels of the GlyR β subunit were associated with the hyperekplexic phenotype in mice ([@bib1]). This hypothesis was tested and supported by the subsequent electrophysiological recordings, which indicated that only pre- and extra-synaptic GABA~A~Rs were impaired in the brainstem hypoglossal nucleus of hyperekplexic mice. Therefore, this study reveals that the pre- and extra-synaptic GABA~A~Rs, specifically the α~5~ subunit-containing GABA~A~Rs primarily located in brainstem hypoglossal nucleus, are novel primary targets in hyperekplexia. This hypothesis is supported by our finding that the GABA~A~Rα~5~ and GlyRα~1~ subunits are colocalized in the brainstem hypoglossal nucleus in GlyRα~1~ S267Q and WT mutant mice as revealed by RNAscope technology. DIA, which has been widely used to treat hyperekplexia in the clinic ([@bib17], [@bib1], [@bib48]), indeed specifically rescued the deficiency of pre- and extra-synaptic α~5~-containing GABA~A~Rs in the HEK-293 cells and mouse brainstem hypoglossal nucleus and restored the exaggerated startle reflex behaviors in the hyperekplexic mutant mice. Thus, developing specific GABA~A~Rα~5~ agonists or modulators may be critical for the treatment of hyperekplexia without producing the major psychoactive or sedative side effects that are associated with benzodiazepines, such as DIA. Such dynamic changes in pre- and extra-synaptic GlyR-GABA~A~R complexes may also contribute to various physiological and pathological processes, such as pain, anxiety, and sleep disorders ([@bib6], [@bib7], [@bib11], [@bib53], [@bib54]). Thus, this GlyR-GABA~A~R interaction not only leads to human hyperekplexia but also may contribute to various neurological disorders involving GlyR and GABA~A~R deficiency.

Limitations of the Study {#sec3.1}
------------------------

Although we identified the interaction between GlyR and GABA~A~R in the brain of hyperekplexic transgenic mice, the detailed interaction pattern and interaction sites between both receptors remain unsolved in the present study. Future research should consider utilizing more advanced molecular biology approaches to clarify the detailed mechanisms involved.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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